Prime Medicine Bio (PRME) - Company Short-Term Debt

Prime Medicine (PRME) - corporate logo

Prime Medicine, Inc. (PRME) adheres to ethical data standards and minimizes environmental impact through waste remediation. The company is implementing automated stations for 24/7 cell cultivation to accelerate therapy development. The business aims for monetization via patent licensing, which will ensure high margins. The current metric stands at 0.01, and the market fluctuations in share price are presented below.

PRME (Prime Medicine) Short-Term Debt Volume history from 04/28/2023 to 10/31/2026

Analytical breakdowns and data insights for company Prime Medicine Bio (PRME)

- current quotes and average value forecast:
Price Chart Prime Medicine|PRME - Forecast Levels Chart
- market capitalization indicators:
Market Value Prime Medicine, Inc.|PRME - Value Adjusted for Debt and Cash
- shareholders' equity book value data:
Book Value per Share Prime Medicine|PRME - Book Valuation of Business|Market Value to Book Value Ratio primemedicine.com|PRME - Cumulative Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Prime Medicine, Inc.|PRME - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Prime Medicine, Inc.|PRME - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Prime Medicine, Inc.|PRME - Company Long-Term Liabilities|Company Short-Term Debts Prime Medicine|Quick Ratio primemedicine.com
- net income and valuation multiples indicators:
PRME - Company Profit
General company analysis:PRME - Prime Medicine
Manufactured products of primemedicine.com

Prime Medicine, Inc. (PRME) is developing a unique prime editing technology for the monopolistic treatment of hereditary pathologies. This metric aggregates all of the issuer's obligations with a maturity of up to one year. Investors utilize this indicator to assess current liquidity and default risks. An increase in debt without a proportional rise in revenue signals financial instability. By analyzing the structure of short-term debt, one can promptly identify hidden threats prior to the publication of official reports.

Competitor analysis

TEM - Company Short-Term Debt|Current Liabilities QGEN|Ionis Pharma (IONS) - Company Short-Term Debt|Repligen Inc. - Company Short-Term Loans and Borrowings|RNA (Avidity Biosciences) - Company Short-Term Debts|crisprtx.com (CRSP) - Short-Term Debt Volume|Company Short-Term Debt GeneDx (WGS)|Company Current Liabilities Ultragenyx Pharmaceutical Inc. RARE|Company Short-Term Debts BEAM (Beam Therapeutics Corp)|Sarepta Corp (SRPT) - Short-Term Debt|TWST: Company Current Liabilities|Company Short-Term Loans and Borrowings TXG (10xgenomics.com)|Intellia Therapeutics, Inc. (NTLA) - Company Short-Term Debt|Company Current Liabilities Stoke Therapeutics Inc|BLFS (BioLife Corp) - Company Short-Term Debts|Short-Term Debt Wave Pharma WVE|Company Short-Term Debts MAZE|sionnatx.com - Company Short-Term Indebtedness|Company Short-Term Debts TSHA (Taysha Gene Therapies, Inc.)|Short-Term Debt Volume uniQure NV (QURE)|MeiraGTx PLC - Company Short-Term Debts|REGENXBIO Corp (RGNX) - Company Current Liabilities|SLDB: Company Short-Term Debts|OCGN - Short-Term Debt Volume|Company Short-Term Debt PacBio|Company Short-Term Indebtedness BNTC (Benitec Biopharma Inc)|Company Short-Term Debts DSGN|RCKT - Short-Term Debt|4D Molecular Therapeutics - Company Current Liabilities|Company Short-Term Loans and Borrowings LXEO|Korro Bio, Inc - Company Short-Term Debts|Short-Term Debt Volume Editas Medicine Inc EDIT|Silence Therapeutics Inc. (SLN) - Company Short-Term Debt|Company Short-Term Indebtedness PRQR|CDXS (Codexis Inc) - Company Short-Term Debts|Company Current Liabilities sangamo.com (SGMO)|Company Current Liabilities NAUT (Nautilus Biotechnology)|Short-Term Debt Volume Metagenomi Inc.|Company Short-Term Debt Precision BioSciences DTIL|GBIO (Generation Bio Co) - Current Liabilities|BOLD - Company Short-Term Debt|Company Short-Term Loans and Borrowings XCUR (Exicure, Inc.)|imunon.com (IMNN) - Company Short-Term Debt|Company Current Liabilities Phio Pharmaceuticals Corp.|MBIO (Mustang Bio Inc) - Company Short-Term Debts|Short-Term Debt TransCode RNAZ|Company Short-Term Debts BNGO|adnas.com - Company Short-Term Indebtedness|Company Short-Term Debt bluebird bio BLUE|IPA: Company Short-Term Indebtedness|Omega - Company Short-Term Debts|OMIC - Company Short-Term Debts|Regulus Therapeutics (RGLS) - Company Short-Term Debt|Current Liabilities SYRS (syros.com)|Company Short-Term Debt Telesis Bio|TCON: Company Short-Term Loans and Borrowings|Company Short-Term Debts UBX